infohep news

• Eligibility for treatment

  One million people with hepatitis C in the US at high priority for treatment

  Liz Highleyman / 07 January 2015

  An estimated 813,000 people with diagnosed hepatitis C in the US have undergone liver disease staging and meet the 'highest' or 'high' priority criteria for immediate treatment, according to an analysis presented ...

• Prognosis and disease progression

  Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer

  Liz Highleyman / 07 January 2015

  Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within five years, and 23% and 11%, respectively, died, according to a study presented ...

• Cirrhosis

  Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis

  Liz Highleyman / 07 January 2015

  Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin ...

• Interferon-free regimens

  Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use

  Liz Highleyman / 09 December 2014

  Regimens containing sofosbuvir (Sovaldi) – including sofosbuvir plus simeprevir (Olysio) – work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently ...

• Treatment in liver transplanted

  AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis

  Liz Highleyman / 08 December 2014

  AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis ...